EP4和TNC与急性主动脉夹层发病以及病情严重程度的关系

林庆礼; 张涛; 孙振国; 杨雪峰

doi:10.13201/j.issn.1009-5918.2021.12.010

EP4和TNC与急性主动脉夹层发病以及病情严重程度的关系

- 1. 山东省立第三医院急诊外科(济南, 250000);
- 2. 山东省立医院心脏外科;
- 3. 山东大学齐鲁医院胸心外科

详细信息

通讯作者: 林庆礼,E-mail:linyuqipa@163.com

中图分类号: R543.1

收稿日期: 2021-08-18

Relationship between EP4 and TNC and the incidence and severity of acute aortic dissection

- 1 Department of Emergency Surgery, Shandong Provincial Third Hospital, Jinan, 250000, China;
- 2 Department of Cardiac Surgery, Shandong Provincial Hospital;
- 3 Department of Thoracic and Cardiovascular Surgery, Qilu Hospital of Shandong University

More Information

Corresponding author: LIN Qingli, E-mail: linyuqipa@163.com

Received Date: 18 August 2021

摘要

摘要: 目的:探讨E-前列腺素受体4(EP4)、肌腱蛋白C(TNC)与急性主动脉夹层(AAD)发病以及病情严重程度间的关系。方法:选择2016年2月-2020年1月期间山东省立第三医院收治的73例AAD患者(AAD组),根据DeBakey分型分为:Ⅰ型组(35例)、Ⅱ型组(20例)和Ⅲ型组(18例),根据是否发生院内死亡将患者分为死亡组(10例)和存活组(63例),另选择62例体检志愿者为对照组。AAD组入院当日、入院3 d、入院7 d(对照组体检当日)采集静脉血,检测血清EP4和TNC水平,收集临床相关资料。采用多因素Logistic回归分析EP4、TNC与AAD发生的关系,绘制受试者工作特征曲线(ROC),分析EP4和TNC诊断AAD的价值。结果:AAD患者入院后血清EP4水平先降低后升高(P<0.05),血清TNC水平先升高后回落(P<0.05)。AAD组、DeBakey分型Ⅰ型组、死亡组入院当日、入院3 d、入院7 d血清EP4水平低于对照组、Ⅱ型组和Ⅲ型组、存活组(P<0.05),血清TNC水平高于对照组、Ⅱ型组和Ⅲ型组、存活组(P<0.05)。高血压(OR=2.214,95%CI:1.544~3.176)、入院当日低水平EP4(OR=0.618,95%CI:0.495~0.771)、入院当日高水平TNC(OR=1.759,95%CI:1.276~2.426)是AAD发病的危险因素(P<0.05)。入院当日EP4、入院当日TNC诊断AAD的曲线下面积为0.773、0.736,TNC与D-二聚体曲线下面积接近,EP4略低于D-二聚体(Z_{D-二聚体vs. EP4、TNC}=2.044、0.906,P=0.041、0.365),联合EP4和TNC后诊断AAD的曲线下面积为0.911,高于单独EP4、TNC以及D-二聚体(Z=4.267、3.503、3.181,P<0.05)。结论:AAD患者血清EP4水平下降、TNC水平增高,且与AAD发病、DeBakey分型以及预后有关,可作为AAD早期识别的辅助生物学指标。
- E-前列腺素受体4 /
- 肌腱蛋白C /
- 急性主动脉夹层 /
- DeBakey分型 /
- 诊断
Abstract: Objective:To investigate the relationship between E-prostaglandin receptor 4(EP4), Tenascin-C(TNC) and the incidence and severity of acute aortic dissection(AAD).Methods:Seventy-three patients with AAD(AAD group) admitted to the department in our hospital from February 2016 to January 2020 were selected. According to DeBakey classification, they were divided into three groups:type Ⅰ group(35 cases), type Ⅱ group(20 cases) and type Ⅲ group(18 cases), and were divided into death group(10 cases) and survival group(63 cases) according to whether in-hospital death occurred. Another 62 volunteers were selected as control group. Blood samples of AAD group were collected on admission day, day 3 and day 7(the day of physical examination of control group), serum EP4 and TNC levels were detected, and clinical data were collected. Multivariate logistic regression was used to analyze the relationship between EP4, TNC and AAD. Receiver operating characteristic curve(ROC) was drawn to analyze the diagnostic value of EP4 and TNC in AAD.Results:After admission, serum EP4 level of AAD patients decreased first and then increased(P<0.05), and serum TNC level increased first and then decreased(P<0.05). The serum EP4 levels of AAD group, DeBakey typeⅠ group and death group were lower those of control group, type Ⅱ-Ⅲ group and survival group on admission day, day 3 and day 7(P<0.05), and the serum TNC levels were higher than those of control group, type Ⅱ-Ⅲ group and survival group(P<0.05), Hypertension(OR=2.214, 95%CI:1.544-3.176), low EP4 on admission day(OR=0.618, 95%CI:0.495-0.771), high TNC on admission day(OR=1.759, 95%CI:1.276-2.426) were risk factors for AAD(P<0.05). The area under the curve of EP4 and TNC diagnosis AAD on admission day were 0.773 and 0.736, the area under the curve of TNC was close to that of D-dimer, and EP4 was slightly lower than D-dimer(Z _{D-dimer vs. EP4, TNC}=2.044, 0.906; P=0.041, 0.365). The area under the curve of AAD diagnosed by EP4 combined with TNC was 0.911, which was higher than EP4, TNC and D-dimer alone(Z=4.267, 3.503, 3.181, P<0.05).Conclusion:The decreased level of serum EP4 and increased level of TNC in AAD patients are related to the pathogenesis, DeBakey classification and prognosis of AAD, and can be used as an auxiliary biological indicator for early identification of AAD.
- E-prostaglandin receptor 4 /
- tendinin C /
- acute aortic dissection /
- DeBakey type points /
- diagnosis

HTML全文

参考文献(18)

[1]	Cheng M,Yang Y,Xin H,et al.Non-coding RNAs in aortic dissection:From biomarkers to therapeutic targets[J].J Cell Mol Med,2020,24(20):11622-11637.
[2]	Ohle R,Kareemi HK,Wells G,et al.Clinical Examination for Acute Aortic Dissection:A Systematic Review and Meta-analysis[J].Acad Emerg Med,2018,25(4):397-412.
[3]	Xu H,Fang B,Du S,et al.Endothelial cell prostaglandin E2 receptor EP4 is essential for blood pressure homeostasis[J].JCI Insight,2020,5(13):e138505.
[4]	Xu H,Du S,Fang B,et al.VSMC-specific EP4 deletion exacerbates angiotensin II-induced aortic dissection by increasing vascular inflammation and blood pressure[J].Proc Natl Acad Sci USA,2019,116(17):8457-8462.
[5]	Imanaka-Yoshida K,Matsumoto KI.Multiple Roles of Tenascins in Homeostasis and Pathophysiology of Aorta[J].Ann Vasc Dis,2018,11(2):169-180.
[6]	中华心血管病杂志编辑委员会,胸痛规范化评估与诊断共识专家组.胸痛规范化评估与诊断中国专家共识[J].中华心血管病杂志,2014,42(8):627-632.
[7]	Baumann F,Makaloski V,Diehm N.Aortic aneurysms and aortic dissection:epidemiology,pathophysiology and diagnostics[J].Internist(Berl),2013,54(5):535-542.
[8]	谢恩泽华,丘俊涛,吴进林,等.主动脉夹层发病机制研究进展[J].中国胸心血管外科临床杂志,2020,27(9):1081-1086.
[9]	Hao H,Hu S,Wan Q,et al.Protective Role of mPGES-1(Microsomal Prostaglandin E Synthase-1)-Derived PGE2(Prostaglandin E2) and the Endothelial EP4(Prostaglandin E Receptor)in Vascular Responses to Injury[J].Arterioscler Thromb Vasc Biol,2018,38(5):1115-1124.
[10]	Zhu L,Xu C,Huo X,et al.The cyclooxygenase-1/mPGES-1/endothelial prostaglandin EP4 receptor pathway constrains myocardial ischemia-reperfusion injury[J].Nat Commun,2019,10(1):1888.
[11]	Cao RY,St Amand T,Li X,et al.Prostaglandin receptor EP4 in abdominal aortic aneurysms[J].Am J Pathol,2012,181(1):313-321.
[12]	Mamun A,Yokoyama U,Saito J,et al.A selective antagonist of prostaglandin E receptor subtype 4 attenuates abdominal aortic aneurysm[J].Physiol Rep,2018,6(18):e13878.
[13]	Li ZL,Zhang HL,Huang Y,et al.Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation[J].Nat Commun,2020,11(1):3806.
[14]	Imanaka-Yoshida K,Yoshida T,Miyagawa-Tomita S.Tenascin-C in development and disease of blood vessels[J].Anat Rec(Hoboken),2014,297(9):1747-1757.
[15]	Imanaka-Yoshida K,Aoki H.Tenascin-C and mechanotransduction in the development and diseases of cardiovascular system[J].Front Physiol,2014,5:283.
[16]	Hamza O,Kiss A,Kramer AM,et al.Tenascin C promotes valvular remodeling in two large animal models of ischemic mitral regurgitation[J].Basic Res Cardiol,2020,115(6):76.
[17]	Kimura T,Shiraishi K,Furusho A,et al.Tenascin C protects aorta from acute dissection in mice[J].Sci Rep,2014,4:4051.
[18]	Trescher K,Thometich B,Demyanets S,et al.Type A dissection and chronic dilatation:tenascin-C as a key factor in destabilization of the aortic wall[J].Interact Cardiovasc Thorac Surg,2013,17(2):365-370.